DataMeds AI Inc. (MEDS)
NASDAQ: MEDSHealth CareOther PharmaceuticalsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
MEDS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $7.67M
- EPS (TTM)
- -$18.39
- Dividend yield
- None
- 52-week range
- 0.493 – 33.15
- Day range
- 0.8552 – 1.43
- Volume / Avg
- 89.98M / 8.43M
- Beta
- —
- Shares outstanding
- 5.72M
52-week range
MEDS stock today
DataMeds AI (MEDS) closed at $1.34 on Nov 20, up 84.14% (+$0.6123), versus the S&P 500's 3.70% decline. Volume was 10.7x the average at 89.98M shares, a sign of unusually heavy trading. Shares are 96.0% below their 52-week high of $33.15 and 171.8% above the 52-week low of $0.493, near the bottom of the past year's range.
DataMeds AI has posted a net loss over the last twelve months (EPS of -$18.39), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About DataMeds AI
Company profileDataMEDS AI, Inc. operates as a health IT company in the United States. The company focuses on the vertical integration of technology, pharmacy, pharmaceutical-adjacent, and telemedicine business units to deliver an enhanced healthcare experience for consumers.
- Sector
- Health Care
- Industry
- Other Pharmaceuticals
- CEO
- Mr. Prashant Patel M.Sc., R.Ph.
- Headquarters
- Tampa, FL
- IPO year
- 2025
- Website
- datamedsai.com
Financial highlights
Full financialsIn fiscal 2025, DataMeds AI generated $23.3 million in revenue, up 28.7% from fiscal 2024. DataMeds AI reported a net loss of $101.3 million, compared with a loss of $6.9 million a year earlier. Gross margin was -27.5% (down from 9.7%) and operating margin -401.7%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Revenue | $23.34M | $18.13M | — |
| Growth | +28.73% | — | — |
| Net income | $-101.27M | $-6.86M | $-2.90M |
| EPS (diluted) | $-1.43 | $-0.15 | $-0.06 |
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 18, 2026
- EPS actual vs est.
- $2.72 vs —
MEDS news
All MEDS news- Datavault AI、技術ライセンス拡大の対価としてDataMEDS AIの株式持分19.9%の取得に向け拘束力のない意向表明書に署名Business WireDVLT, MEDS
- Datavault AI firma una carta de intención no vinculante para adquirir el 19,9 % del capital de DataMEDS AI a cambio de ampliar una licencia tecnológicaBusiness WireDVLT, MEDS
- Datavault AI unterzeichnet unverbindliche Absichtserklärung zum Erwerb von 19,9 Prozent an DataMEDS AI im Gegenzug für die Erweiterung einer TechnologielizenzBusiness WireDVLT, MEDS
- Datavault AI簽署不具約束力的意向書,擬收購DataMEDS AI的19.9%股權以擴大技術授權Business WireDVLT, MEDS
- Samenvatting: Datavault AI ondertekent een vrijblijvende intentieovereenkomst om een aandelenbelang van 19,9% in DataMEDS AI te verwerven met het oog op een uitgebreide technologielicentieBusiness WireDVLT, MEDS
- Datavault AI assina uma carta de intenções não vinculativa para adquirir 19,9% das ações da DataMEDS AI, em troca de uma licença ampliada de tecnologiaBusiness WireDVLT, MEDS
- Riassunto: Datavault AI firma una lettera di intenti non vincolante per acquisire una quota azionaria del 19,9% in DataMEDS AI in vista di una licenza tecnologica estesaBusiness WireDVLT, MEDS
- Datavault AI Signs Non-Binding Letter of Intent to Acquire a 19.9% Equity Stake in DataMEDS AI in Consideration of an Expanded Technology LicenseBusiness WireDVLT, MEDS
DataMeds AI peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| HKPDCellyan Biotechnology Co. Ltd Class A | 1.38 | +2.60% | $3.40M | vs MEDS |
| COSMCosmos Health Inc. | 2.81 | -2.09% | $14.14M | vs MEDS |
| ESYNEnerSyn Global Inc. | 1.11 | -0.89% | $37.44M | vs MEDS |
| NUSNu Skin Enterprises Inc. | 3.80 | +0.80% | $184.98M | vs MEDS |
| HLFHerbalife Ltd. | 15.53 | -0.26% | $1.63B | vs MEDS |
| CAHCardinal Health Inc. | 272.81 | +0.17% | $63.06B | vs MEDS |
| CORCencora Inc. | 339.09 | -0.63% | $64.71B | vs MEDS |
| MCKMcKesson Corporation | 1,069.43 | +0.68% | $123.47B | vs MEDS |
Indexes, lists and sector
DataMeds AI stock FAQ
What is DataMeds AI's stock price today?
MEDS last traded at $1.34 as of Nov 20, 4:00 PM EST, up 84.14% on the day. Prices are delayed at least 15 minutes.
Who is DataMeds AI's CEO?
Mr. Prashant Patel M.Sc., R.Ph. is the chief executive officer of DataMeds AI Inc..
What is the MEDS 52-week high?
The 52-week high for MEDS is $33.15 and the 52-week low is $0.493. The stock is currently 96.0% below its high.